VREOF Vireo Growth Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1771706 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY255.9%
TTM net income YoY-2.2%
TTM EPS YoY149.6%
Revenue 3-yr CAGR101.0%
Net income 3-yr CAGR—
Margins
Gross margin47.4%
Operating margin1.3%
Net margin-9.6%
FCF margin-14.6%
EBITDA margin5.4%
Returns
ROE-17.5%
ROA-6.2%
ROIC (approx.)3.3%
Asset turnover0.64x
Leverage & solvency
Liabilities / assets65.3%
Debt / equity0.00x
Current ratio1.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.58x
Accruals ratio-9.7%
Payout ratio—
Capex / revenue20.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $268.77M | $99.38M |
| Gross profit | $127.10M | $50.77M |
| SG&A expense | $81.19M | $28.06M |
| Operating income | -$1.05M | $13.56M |
| Interest expense | — | $31.19M |
| Pretax income | -$39.91M | -$16.89M |
| Income tax | $28.23M | $11.11M |
| Net income | -$68.11M | -$28.01M |
| EBITDA | $15.06M | $16.10M |
| EPS (basic) | -0.09 | -0.16 |
| EPS (diluted) | -0.09 | -0.16 |
| Weighted avg. shares (diluted) | 734.74M | 180.39M |
| Balance sheet | ||
| Cash & equivalents | $122.50M | $91.60M |
| Short-term investments | $1.00M | — |
| Receivables | $12.70M | $2.87M |
| Inventory | $60.00M | $21.67M |
| Current assets | $305.10M | $230.37M |
| PP&E, net | $217.50M | $32.31M |
| Goodwill | $87.50M | $0 |
| Intangibles | $117.50M | $7.90M |
| Total assets | $817.20M | $278.86M |
| Current liabilities | $191.70M | $135.47M |
| Total liabilities | $509.80M | $223.30M |
| Shareholders' equity | $307.40M | $55.50M |
| Cash flow statement | ||
| Operating cash flow | $3.71M | -$10.23M |
| Capital expenditure | $28.32M | $11.69M |
| Free cash flow | -$24.61M | -$21.93M |
| Investing cash flow | $8.76M | -$8.13M |
| Financing cash flow | $18.42M | $94.01M |
| Depreciation & amortization | $16.11M | $2.54M |
| Stock-based compensation | $18.66M | $3.63M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.